11 October 2024
Braveheart Investment Group plc
("Braveheart" or the "Company")
Acquisition of Interest in IQ-AI Limited
and
Related Party Transaction
Braveheart Investment Group (AIM: BRH), announces the acquisition of 65,415,862 ordinary shares of
45,761,083 shares in IQ-AI have been purchased from Trevor Brown, CEO of Braveheart, at a price of
IQ-AI is an imaging software and healthcare diagnostics company, whose subsidiaries include Imaging Biometrics, LLC ("IB") and Stone Checker Software Limited. IB is a healthcare imaging software company that supplies medical technology solutions, regulatory consulting services and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention. IQ-AI's ordinary shares are listed on the main market of the London Stock Exchange. Trevor Brown is the CEO of IQ-AI.
In the year ended 31 December 2023, IQ-AI made a loss before tax of approximately
The independent directors of Braveheart were offered an opportunity to acquire a substantial stake in IQ-AI. They considered that IB is making progress in its Phase 1 Clinical Trial of gallium maltolate, as reported by IQ-AI on 13 August 2024. The IQ-AI business fits well with Braveheart's investment strategy and will make an attractive addition to Braveheart's investment portfolio at what the board considered is an attractive entry price.
Related Party Transaction
Trevor Brown and FAB are deemed to be related parties under the AIM Rules for Companies. The independent directors, being Qu Li, Susan Hagan and Vivian Hallam, consider, having consulted with Allenby Capital Limited, the Company's Nominated Adviser, that the terms of the purchase of the IQ-AI shares is fair and reasonable insofar as the shareholders of Braveheart are concerned.
For further information:
Braveheart Investment Group plc |
Tel: 01738 587555 |
Trevor Brown CEO |
|
|
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
James Reeve / George Payne |
|
|
|
Peterhouse Capital Limited (Joint Broker) |
Tel: 020 7469 0936 |
Duncan Vasey / Lucy Williams |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.